Aurora Oncology, Inc.

Aurora Oncology develops targeted biologics to satisfy the unmet need of improved efficacy and safety of bladder cancer therapy.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Aurora, CO, USA
  • Currency USD
  • Founded November 2011
  • Employees 2
  • Website --

Company Summary

Aurora Oncology is focused on the development and commercialization of unique biologics for the treatment of superficial bladder cancer. DAB389EGF and Nano-EGFR work by targeting specific receptors on the surface of cancer cells. Nano-EGFR also allows for imaging of bladder cancer in the patient resulting in the potential for targeted therapy. Both of these products are poised to enter clinical development.

Team

  • Mike Glode, M.D.
    Founder and President

    Professor of Medicine (Medical Oncology), University of Colorado School of Medicine

  • Tom Flaig, M.D.
    Founder and VP-EGFR Targets

    Associate Professor of Medicine (Medical Oncology), University of Colorado School of Medicine

  • Dan Theodorescu, M.D.
    Founder and VP-Ral Targets

    Head, University of Colorado Comprehensive Cancer Center;
    Professor of Surgery and Medicine (Medical Oncology), University of Colorado School of Medicine

  • Thomas Flaig

Advisors

  • Brent Fassett, Cooley LLP
    Lawyer
    Unconfirmed
    N/A
    Accountant
    Unconfirmed

Previous Investors

  • N/A
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free